Soluble mediators of relapse
复发的可溶性介质
基本信息
- 批准号:10611346
- 负责人:
- 金额:$ 57.42万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-05-01 至 2026-04-30
- 项目状态:未结题
- 来源:
- 关键词:ANGPTL4 geneAcuteAlbuminuriaAllelesAnimal Disease ModelsAntibodiesBALB/cJ MouseBindingBody SurfaceCRISPR/Cas technologyCell NucleusCell membraneCellsCommon ColdCommon Cold VirusCytokine ReceptorsDependenceDevelopmentDiseaseDissociationDown-RegulationEndothelial CellsEphrin-B1EventExclusionFocal and Segmental GlomerulosclerosisGenesGenomicsGlucocorticoidsHistologyHodgkin DiseaseHomeoboxHomeodomain ProteinsHumanIL-13Ralpha1Inbred BALB C MiceIndividualInfectionInjectionsInnate Immune ResponseIntercellular adhesion molecule 1Interferon Type IIInterleukin 2 Receptor GammaInterleukin 4 ReceptorInterleukin-10Interleukin-2Interleukin-6KidneyLinkLoxP-flanked alleleMediatingMediatorMembraneModelingMusMyristica fragransNasal EpitheliumNatural ImmunityNatureNuclearPatientsPharmaceutical PreparationsProcessProteinsProteinuriaRattusRecurrent diseaseRelapseRenal glomerular diseaseRhinitisRhinovirusSignal PathwayStimulusSystemTNF geneTherapeuticToxic effectUntranslated RNAVariantZinc Fingersadaptive immune responseadaptive immunitycytokinecytokine release syndromedesignglutamyl aminopeptidasein vivoinsertion/deletion mutationintravenous injectionmembermesangial cellnovelnovel strategiesnovel therapeutic interventionpodocytepreventreceptorrelapse preventionsynergismtargeted treatmenttranscription factor
项目摘要
Abstract
The most common event preceding relapse of primary glomerular diseases like Minimal Change
Disease and Focal and Segmental Glomerulosclerosis is the common cold. Treatment of disease
relapse is a lengthy process involving glucocorticoids and other immunosuppressive medications, some
of which have multi-system toxicity. We hypothesized that relapse is induced by a “cytokine storm” that
follows infection by common cold viruses like Rhinovirus. A “cytokine cocktail” was designed around
the soluble Rhinovirus receptor and induces acute albuminuria after single intravenous injection in mice
with low podocyte Zhx2 expression, a common feature in MCD and FSGS patients. This cytokine
cocktail comprises of components of the innate and adaptive immune response that are necessary and
sufficient to induce acute albuminuria. Exclusion of any member from the cytokine cocktail, or injection
of individual members does not induce albuminuria.
In this proposal, we will develop therapeutic strategies to prevent relapse of glomerular diseases after
a common cold, by depleting soluble cytokines in the cytokine storm, or blocking their receptors in the
glomerulus.
In Aim 1, studies on cytokine depletion or receptor blockage in the podocyte will be conducted, and
receptor dependent and independent mechanisms identified.
In Aim 2, studies on cytokine depletion or receptor blockage in endothelial and mesangial cells will be
conducted, and receptor dependent and independent mechanisms identified.
In Aim 3, a therapeutic strategy that combines cytokine depletion with receptor blockage will be
developed.
摘要
原发性肾小球疾病(如微小病变)复发前最常见的事件
疾病与局灶性节段性肾小球硬化症是普通感冒。治疗疾病
复发是一个漫长的过程,涉及糖皮质激素和其他免疫抑制药物,
具有多系统毒性。我们假设复发是由“细胞因子风暴”引起的,
是由鼻病毒等普通感冒病毒引起的。设计了一种“细胞因子鸡尾酒”,
可溶性鼻病毒受体,并诱导小鼠单次静脉注射后急性蛋白尿
足细胞Zhx2表达较低,这是MCD和FSGS患者的共同特征。这种细胞因子
鸡尾酒由先天性和适应性免疫应答的必要组分组成,
足以引起急性蛋白尿。从细胞因子混合物或注射中排除任何成员
个别成员的不诱导蛋白尿。
在这项提案中,我们将制定治疗策略,以防止肾小球疾病复发后,
普通感冒,通过消耗细胞因子风暴中的可溶性细胞因子,或阻断细胞因子风暴中的受体,
肾小球
在目标1中,将进行足细胞中细胞因子耗竭或受体阻断的研究,
确定了受体依赖性和非依赖性机制。
在目标2中,将对内皮细胞和系膜细胞中细胞因子耗竭或受体阻断进行研究。
进行,并确定受体依赖和独立的机制。
在目标3中,将细胞因子耗竭与受体阻断相结合的治疗策略将是:
开发
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Cytokine storm-based mechanisms for extrapulmonary manifestations of SARS-CoV-2 infection.
- DOI:10.1172/jci.insight.166012
- 发表时间:2023-05-22
- 期刊:
- 影响因子:8
- 作者:Avila, Maria Del Nogal;Das, Ranjan;Kharlyngdoh, Joubert;Molina-Jijon, Eduardo;Blazquez, Hector Donoro;Gambut, Stephanie;Crowley, Michael;Crossman, David K.;Gbadagesin, Rasheed A.;Chugh, Sunveer S.;Chugh, Sunjeet S.;Avila-Casado, Carmen;Mace, Camille;Clement, Lionel C.;Chugh, Sumant S.
- 通讯作者:Chugh, Sumant S.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sumant Singh Chugh其他文献
Sumant Singh Chugh的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sumant Singh Chugh', 18)}}的其他基金
Investigation of non-HIV Collapsing Glomerulopathy
非 HIV 塌陷性肾小球病的调查
- 批准号:
9750079 - 财政年份:2016
- 资助金额:
$ 57.42万 - 项目类别:
Renal Protective Effects of Circulating Angiopoietin-like-4
循环血管生成素样 4 的肾脏保护作用
- 批准号:
8816097 - 财政年份:2014
- 资助金额:
$ 57.42万 - 项目类别:
Renal Protective Effects of Circulating Angiopoietin-like-4
循环血管生成素样 4 的肾脏保护作用
- 批准号:
9002042 - 财政年份:2014
- 资助金额:
$ 57.42万 - 项目类别:
相似海外基金
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 57.42万 - 项目类别:
Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 57.42万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 57.42万 - 项目类别:
Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 57.42万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 57.42万 - 项目类别:
Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 57.42万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 57.42万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 57.42万 - 项目类别:
Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 57.42万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
- 批准号:
2244994 - 财政年份:2023
- 资助金额:
$ 57.42万 - 项目类别:
Standard Grant














{{item.name}}会员




